| Bioactivity | Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC50 of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, cocaine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential treatment for multiple forms of drug abuse[1]. Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis[2]. |
| Target | IC50: 0.90 μM (nicotinic α3β4 receptor) |
| Invitro | Zolunicant (18-MC; 0.01-100 μM) shows an inhibitory activity against nicotinic α3β4 receptors with an IC50 of 0.90 μM[1].. Zolunicant (18-MCOR; 0-20 μg/ml; 24h) also shows antiamastigote activity against L. amazonensis-infected macrophage[2]. Cell Viability Assay[2] Cell Line: |
| In Vivo | Zolunicant (18-MC; Intravenous administration; 0-20 μg a day;14 days) decreases morphine self-administration by blocking α3β4 nicotinic receptors in the habenulo-interpeduncular pathway[3]. Animal Model: |
| Name | Zolunicant |
| CAS | 188125-42-0 |
| Formula | C22H28N2O3 |
| Molar Mass | 368.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pace CJ, et al. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European journal of pharmacology. 2004;492(2-3):159-67. [2]. Delorenzi JC, et al. In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis. Antimicrob Agents Chemother. 2002;46(7):2111-5. [3]. Glick SD, et al. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. European journal of pharmacology. 2006;537(1-3):94-8. |